Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 283

1.

Primary care issues in patients with mental illness.

Kiraly B, Gunning K, Leiser J.

Am Fam Physician. 2008 Aug 1;78(3):355-62.

2.

[Drawing up guidelines for the attendance of physical health of patients with severe mental illness].

Saravane D, Feve B, Frances Y, Corruble E, Lancon C, Chanson P, Maison P, Terra JL, Azorin JM; avec le soutien institutionnel du laboratoire Lilly.

Encephale. 2009 Sep;35(4):330-9. doi: 10.1016/j.encep.2008.10.014. Epub 2009 Jul 9. French.

PMID:
19748369
3.

[Psychotropic drugs induced weight gain: a review of the literature concerning epidemiological data, mechanisms and management].

Ruetsch O, Viala A, Bardou H, Martin P, Vacheron MN.

Encephale. 2005 Jul-Aug;31(4 Pt 1):507-16. Review. French.

PMID:
16389718
4.

Treating the mind and body in schizophrenia: risks and prevention.

Meyer JM.

CNS Spectr. 2004 Oct;9(10 Suppl 11):25-33.

PMID:
15475874
5.

Comparing the safety and efficacy of atypical antipsychotics in psychiatric patients with comorbid medical illnesses.

Newcomer JW.

J Clin Psychiatry. 2009;70 Suppl 3:30-6. doi: 10.4088/JCP.7075su1c.05. Review.

6.
7.
8.

Metabolic syndrome and mental illness.

Newcomer JW.

Am J Manag Care. 2007 Nov;13(7 Suppl):S170-7. Review. Erratum in: Am J Manag Care. 2008 Feb;14(2):76.

9.

Schizophrenia and comorbid metabolic disorders.

Henderson DC.

J Clin Psychiatry. 2005;66 Suppl 6:11-20. Review.

10.

Antipsychotic medications: metabolic and cardiovascular risk.

Newcomer JW.

J Clin Psychiatry. 2007;68 Suppl 4:8-13. Review.

11.

The effects of undertreated chronic medical illnesses in patients with severe mental disorders.

Fagiolini A, Goracci A.

J Clin Psychiatry. 2009;70 Suppl 3:22-9. doi: 10.4088/JCP.7075su1c.04. Review.

12.

Adverse effects of antipsychotic medications.

Muench J, Hamer AM.

Am Fam Physician. 2010 Mar 1;81(5):617-22. Review.

13.

Assessing cardiovascular risks versus clinical benefits of atypical antipsychotic drug treatment.

Meltzer HY, Davidson M, Glassman AH, Vieweg WV.

J Clin Psychiatry. 2002;63 Suppl 9:25-9. Review.

14.
15.

Risk of cardiovascular disease and sudden death in schizophrenia.

Davidson M.

J Clin Psychiatry. 2002;63 Suppl 9:5-11. Review. Erratum in: J Clin Psychiatry 2002 Aug;63(8):744.

16.

Metabolic and cardiovascular adverse events associated with antipsychotic treatment in children and adolescents.

McIntyre RS, Jerrell JM.

Arch Pediatr Adolesc Med. 2008 Oct;162(10):929-35. doi: 10.1001/archpedi.162.10.929.

PMID:
18838645
17.

Description of a healthy lifestyle intervention for people with serious mental illness taking second-generation antipsychotics.

Park T, Usher K, Foster K.

Int J Ment Health Nurs. 2011 Dec;20(6):428-37. doi: 10.1111/j.1447-0349.2011.00747.x. Epub 2011 May 12.

PMID:
21564457
18.

Schizophrenia and obesity: impact of antipsychotic medications.

Wirshing DA.

J Clin Psychiatry. 2004;65 Suppl 18:13-26. Review.

19.

Metabolic issues and cardiovascular disease in patients with psychiatric disorders.

Casey DE.

Am J Med. 2005 Apr;118 Suppl 2:15S-22S. Review.

PMID:
15903291
20.

Impact of patients' preexisting metabolic risk factors on the choice of antipsychotics by office-based physicians.

Li C, Mittal D, Owen RR.

Psychiatr Serv. 2011 Dec;62(12):1477-84. doi: 10.1176/appi.ps.000882011.

PMID:
22193796

Supplemental Content

Support Center